Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies
Authors:
- 26 March 2022
- book chapter
- Published by Elsevier
- Vol. 156, 367-413
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
- Roche España
- Eisai
- Bristol-Myers Squibb
This publication has 201 references indexed in Scilit:
- Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinomaHepatology, 2013
- Predictive clinical outcome of the intratumoral CD66b‐positive neutrophil‐to‐CD8‐positive T‐cell ratio in patients with resectable nonsmall cell lung cancerCancer, 2011
- Interleukin‐17‐educated monocytes suppress cytotoxic T‐cell function through B7‐H1 in hepatocellular carcinoma patientsEuropean Journal of Immunology, 2011
- Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and functionTrends in Immunology, 2011
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor MicroenvironmentCancer Cell, 2009
- Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of miceNature Immunology, 2006
- Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinomaJournal of Hepatology, 2004
- Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acidInternational Journal of Cancer, 2003
- Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinomaHepatology, 1997